Rheumatoid arthritis (RA) is a chronic, disabling, inflammatory polyarthritis that affects patient well-being and QOL. Many disease-modifying antirheumatic drugs (DMARDs) are available for treating RA but patients are often refractory to treatment. The goal of treatment is to improve both general health and health-related QOL. Generic and disease-specific instruments exist to measure QOL. Using these instruments, one can determine if QOL improves with treatment. If the minimal clinically important difference (MCID) for the instrument is known, one can determine if the change is clinically significant.
The literature was reviewed in a systematic manner to determine which drugs could affect QOL in patients with refractory RA. Refractory RA is poorly defined but we used the definition of failing at least two DMARDs. Methotrexate, leflunomide, cyclosporin, glucocorticoids, etanercept and infliximab clinically and statistically significantly improved QOL in patients with RA. Gold and epoetin-α (erythropoietin) statistically improved QOL in patients with RA but the clinical significance of the improvements could not be determined. These studies were either in non-refractory populations or the refractoriness could not be determined. Further study is required to determine the response of QOL to treatment in patients with refractory RA and instruments with known MCIDs should be used so that the clinical significance of the improvement can be determined.
Rheumatoid Arthritis Infliximab Etanercept Minimal Clinically Important Difference Health Assessment Questionnaire
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
The authors would like to thank Jessie McGowan for her assistance with the literature search for this article. Dr Tugwell is a paid consultant for and has received grants from a variety of pharmaceutical companies. There was no specific funding for this study.
Krause D, Schleusser B, Herborn G, et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14–21PubMedCrossRefGoogle Scholar
Van de Putte LBA, Kroot EJA, van Riel PLCM. Management of refractory rheumatoid arthritis. Rheumatology 1999; 38 Suppl. 2: 32–4PubMedGoogle Scholar
Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35PubMedCrossRefGoogle Scholar
Tuttleman M, Pillemer SR, Tilley BC, et al. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. J Rheumatol 1997; 24: 1910–5PubMedGoogle Scholar
Clinch J, Tugwell P, Wells G, et al. Individualized functional priority approach to the assessment of health related quality of life in rheumatology. J Rheumatol 2001; 28: 445–51PubMedGoogle Scholar
Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993; 153: 1337–42PubMedCrossRefGoogle Scholar
Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43 (7): 1478–87PubMedCrossRefGoogle Scholar
Fries IF. How may quality of life for rheumatoid arthritis patients be enhanced by current and future treatments? Rheumatology 1999; 38 Suppl. 2: 35–40PubMedGoogle Scholar
Buchbinder R, Bombardier C, Yeung M, et al. Which outcome measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum 1995; 38 (11): 1568–80PubMedCrossRefGoogle Scholar
Scott DL, Garrood T. Quality of life measures use and abuse. Baillieres Best Pract Res Clin Rheumatol 2000; 14 (4): 663–87PubMedCrossRefGoogle Scholar
Bombardier C, Ware J, Russell IJ, et al. Auranofin therapy and quality of lie in patients with rheumatoid arthritis: results of a multicenter trial. Am J Med 1986; 81 (4): 565–78PubMedCrossRefGoogle Scholar
Meenan RF, Anderson JJ, Kazis LE, et al. Outcome assessment in clinical trials: evidence for the sensitivity of a health status measure. Arthritis Rheum 1984; 27 (12): 1344–52PubMedCrossRefGoogle Scholar
Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelvemonth, placebo-controlled trial. Arthritis Rheum 2000; 43 (3): 506–14PubMedCrossRefGoogle Scholar
Pouchot J, Guillemin F, Coste J, and the French Quality of Life Rheumatology Group, et al. Validity, reliability and sensitivity to change of a French version of the arthritis impact measurement scales2 (AIMS2) in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1996; 23: 52–60PubMedGoogle Scholar
Tugwell P, Bombardier C, Buchanan WW. Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med 1990; 150: 59–62PubMedCrossRefGoogle Scholar
Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051–5PubMedCrossRefGoogle Scholar
Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137–41PubMedCrossRefGoogle Scholar
Tilley BC, Alarcon GS, Heyse SP, for the MIRA Trial Group, et al. Minocycline in rheumatoid arthritis. A 48-week, double blind, placebo-controlled trial. Ann Intern Med 1995; 122: 81–9PubMedGoogle Scholar
Mathias SD, Colwell HH, Miller DP, et al. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000; 22: 128–39PubMedCrossRefGoogle Scholar
Smolen IS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared to placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353 (9149): 259–66PubMedCrossRefGoogle Scholar
Strand V, Tugwell P, Bombardier C, et al. Function and healthrelated quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42 (9): 1870–8PubMedCrossRefGoogle Scholar
Scott DL. Leflunomide improves quality of life in rheumatoid arthritis. Scand J Rheumatol 1999; 28 Suppl. 112: 23–9CrossRefGoogle Scholar
Bombardier C, Buchbinder R, Tugwell P. Efficacy of cyclosporin A in rheumatoid arthritis: long-term follow-up data and the effect on quality of life. Scand J Rheumatol 1992; 21 Suppl. 95: 29–33CrossRefGoogle Scholar
Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142–6PubMedCrossRefGoogle Scholar
Lipsky PE, Van Der Heijde DMFM, St Clair EW, for the AntiTumour Necrosis Factor Trial In Rheumatoid Arthritis With Concomitant Therapy Study Group, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594–602PubMedCrossRefGoogle Scholar
Peeters HRM, Jongen-Lavrencic M, Bakker CH, et al. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 1999; 18: 201–6PubMedCrossRefGoogle Scholar
Murphy EA, Bell AL, Wojtulewski J, et al. Study of erythropoietin in treatment of anemia in patients with rheumatoid arthritis. BMJ 1994; 309: 1337–8PubMedCrossRefGoogle Scholar
Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89 (2): 161–8PubMedCrossRefGoogle Scholar